Business
PDMR Shareholding
ProBiotix Health plc announced that Michael Litichevski, Vice President of Sales, acquired 45,100 ordinary shares of 0.05p each at a price of 6.5p per share on February 16, 2026, on the Aquis Growth Market. This transaction represents an initial notification of a PDMR shareholding. Disclaimer*
About this update from Probiotix Health Plc
17 February 2026 ProBiotix Health plc ("ProBiotix Health" or the "Company" or, together with its subsidiary, the "Group") PDMR Shareholding ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, is pleased to announce that a PDMR of the Company has acquired 45,100 ordinary shares of 0.05p each in the Company ("Ordinary Shares") as set out in the table below. For further information, please contact: ProBiotix Health plc https://probiotixhealth-ir.com Steen Andersen, Chief Executive Officer Miles Nolan, Investor Relations [email protected] AlbR Capital Limited Aquis Corporate Adviser and Broker Tel: 020 7220 9793 Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them. 1 Details of the person discharging managerial responsibilities / person closely associated a) Name Michael Litichevski 2 Reason for the notification a) Position/status Vice President, Sales b) Initial notification /Amendment Initial 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer, or auction monitor a) Name ProBiotix Health plc b) LEI 98450048683CF0388C30 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instrument Identification code ordinary shares of 0.05p each ISIN: GB00BLNBFR86 b) Nature of the transaction Acquisition of ordinary shares c) Price(s) and volume(s) 45,100 ordinary shares at 6.5p per share d) Aggregated information - Aggregated volume - Price n/a - single transaction e) Date of the transaction 16 February 2026 f) Place of the transaction Aquis Growth Market This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.
View stock analysis, news, and events for Probiotix Health Plc